Navigation Links
FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery
Date:7/1/2011

has been shown to safely and effectively help keep people from developing preventable blood clots," said Alan Brownstein, Chief Executive Officer of the National Blood Clot Alliance. "The FDA approval of a new blood thinner, XARELTO®, offers a new option for patients seeking knee or hip replacement surgery, and we encourage people to discuss with their physicians the risk of blood clots and which blood thinner offers optimal protection as part of their pre-surgical consultation."

Pivotal data from the XARELTO® Phase 3 clinical development program reflected in the approved label showed significantly greater efficacy of rivaroxaban, both in head-to-head comparison with enoxaparin and when comparing extended-duration (5 weeks) rivaroxaban with short-duration (2 weeks) enoxaparin, followed by placebo. In these trials, rivaroxaban and enoxaparin demonstrated similar safety profiles including low rates of major bleeding.

XARELTO® is approved for use at a 10 mg dose, once-daily for 35 days following hip replacement and for 12 days following knee replacement surgery. To date, XARELTO® is approved in more than 110 countries worldwide and has been successfully launched in more than 80 countries by Bayer HealthCare. Janssen Pharmaceuticals, Inc. holds marketing rights for XARELTO® in the U.S. The U.S. Bayer HealthCare sales force will support the Janssen Pharmaceuticals, Inc. sales force by detailing XARELTO® in designated hospital accounts.

"Shorter hospital stays following hip and knee replacement surgeries have made the prevention of venous blood clots an outpatient issue, and XARELTO® provides a safe and effective oral treatment option that can be easily transitioned from use in hospital to home," said Paul Chang, M.D., Vice President, Medical Affairs, Internal Medicine, Janssen Pharmaceuticals, Inc. "We're pleased to make XARELTO® tablets available to physicians to help them better protect their patient
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients
2. FDA Approves First Generic Versions of the Antibiotic Levofloxacin to Treat Certain Infections
3. FDA Approves Nulojix for Kidney Transplant Patients
4. FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
5. FDA Approves First Ceramic-on-Metal Total Hip Replacement System
6. FDA Approves Redesigned Labels for Some Merck Drugs
7. FDA Approves Updates to Lillys Humalog® (insulin lispro injection [rDNA origin]) Label
8. FDA Approves Marketing of RMS Subcutaneous Needle Sets
9. FDA Approves Injectable Gel to Treat Fecal Incontinence
10. FDA approves Incivek for hepatitis C
11. FDA Approves Sutent for Rare Type of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... CardioVascular Institute enrolled the first patient in Pennsylvania ... in a trial assessing the safety and effectiveness ... main artery of the leg. The new stent allows for ... stent fracture or re-narrowing after the stent is placed. ... the BioMimics 3D Stent System and will enroll 280 subjects ...
(Date:8/27/2015)... NEW YORK , Aug. 27, 2015   ... cord tissue , and placenta tissue ... innovative cord blood banking e-commerce website. This new website ... than ever with an interactive shopping cart and checkout ... "Most cord blood banking websites make this ...
(Date:8/27/2015)... 2015  Lightwave Logic, Inc. (OTCQB: LWLG), a ... Generation Photonic Devices and Non-Linear Optical Polymer ... fiber-optic data communications and optical computing, announced today ... appointed to the Company,s Board of Directors. ... optoelectronics is widely recognized with wide-ranging experience across ...
Breaking Medicine Technology:First Pennsylvania Patient Treated in Landmark Vascular Study 2Cord Blood Bank Revolutionizes Process of Online Cord Blood Banking 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3
... /PRNewswire-Asia-FirstCall/ -- China Botanic Pharmaceutical Inc. (AMEX: ... manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional ... made considerable progress in its efforts to comply with ... ("SOX 404") for fiscal year 2010. As ...
... Inc. (Nasdaq: PARD ), a biopharmaceutical company ... has completed the voluntary prepayment of the $12.35 million ... secured loan facility with GE Business Financial Services Inc. ... 16, 2010 that it had provided notice of such ...
Cached Medicine Technology:China Botanic Announces Progress on its SOX 404 Compliance Program 2China Botanic Announces Progress on its SOX 404 Compliance Program 3Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility 2Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility 3Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility 4
(Date:8/27/2015)... ... August 27, 2015 , ... According to the Rocky ... patient with hemophilia is $175,000. Hemophilia is an inherited, life-long condition with no ... RMHBDA exists to help raise funds for patients suffering from bleeding disorders, deliver ...
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... According ... and the American Heart Association have released new guidelines to educate doctors and patients ... last update to these particular guidelines came in 2007, so the new version is ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... , is one of just 20 adult-only medical centers in the United States ... with failing hearts and lungs. The Extracorporeal Life Support Organization (ELSO) , ...
(Date:8/27/2015)... ... August 27, 2015 , ... About 10 percent of mothers ... Gulf Coast, killing more than 1,800 people, displacing hundreds of thousands and causing ... University study. , While most people don’t develop persistent depression after a major ...
(Date:8/27/2015)... ... August 27, 2015 , ... Infocast is ... October 27-29, 2015 in San Jose, CA. The first event dedicated to ... the void that exists where battery development and energy storage innovation are concerned. ...
Breaking Medicine News(10 mins):Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 3Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 4Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2
... growing epidemic of the world,s most common heart rhythm ... admissions in Australia, according to cardiology researchers. A ... University of Adelaide and the Cardiovascular Research Centre at ... to atrial fibrillation had more than tripled in Australia ...
... Elsevier, a world-leading publisher of scientific, technical ... the launch of SciVerse, an innovative platform that ... scientific community to collaborate on the development of ... to releasing the APIs (application programming interfaces) for ...
... available in French . The medicinal use ... the public at large for many years as an alternative ... be effective and may have unwanted side effects. A new ... researchers provides evidence that cannabis may offer relief to patients ...
... , SUNDAY, Aug. 29 (HealthDay News) -- Having a particular ... risk of getting migraines, new research shows. While migraines ... specific genes has proven difficult, the researchers said. The ... genetic variant associated with a heightened risk for the most ...
... cannabis reduces pain, improves mood and helps sleep, ... Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj091414.pdf ... pain due to damage or dysfunction of the ... include opioids, anticonvulsants, antidepressants and local anesthetics, but ...
... Portugal: Many children are being put at risk by ... fever, coughs and colds, says a study from Australia to ... Federation (FIP) today (Monday 30 August). The ... Sydney, New South Wales, say that dosing errors and inappropriate ...
Cached Medicine News:Health News:Heart disorder hits national epidemic proportions 2Health News:Elsevier introduces SciVerse, an innovative platform for accelerating science 2Health News:Research demonstrates benefits of medical cannabis as a treatment for chronic pain 2Health News:New Migraine Gene Discovered 2Health News:New Migraine Gene Discovered 3Health News:Smoked cannabis reduces chronic pain 2Health News:Widespread parental misuse of medicines puts children at risk 2Health News:Widespread parental misuse of medicines puts children at risk 3
Aerosolized Medication Device for Infants. An alternative to aerosol blow-by., ,The PediNeb™ was designed to enhance the delivery of aerosolized medication, while reducing the apprehension enc...
... and Respiratory Products, ,Westmed designs, manufacturers ... Anesthesia and Respiratory professionals. Our mission is ... the clinician's ability to deliver quality medical ... bottom line. , ,Our web site ...
... Applications:, ,Cool Aerosol Therapy. Replaces air ... devices such as aerosol masks, face tents, ... only limited FIO2 and limited flow. The ... against accidental dilution with room air or ...
... For use with metered dose inhalers., ... medication from MDI canisters. Its versatile design ... ventilator circuit, in conjunction with an endotracheal ... oral inhalation. ACE may also be used ...
Medicine Products: